EYPT @ .72 up 40% > EyePoint Pharmaceuticals shares are trading higher after the company announced it has received an upfront payment of $9.5 million after expanding its exclusive license agreements with Ocumension Therapeutics for the development and commercialization of YUTIQ and DEXYCU.
OpGen Announces CE-IVD Marking and Commercial Launch in Europe of its Own Developed Molecular Diagnostic SARS-CoV-2 Kit with PULB for Detection of the Virus Causing COVID-19